Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans

Transplantation

Volumn 50, Issue 3, 1990, Pages 518-521

  Symington, Frank W ^a   Pepe, Margaret Sullivan ^a   Chen, Anthony B ^b   Deliganis, Anna ^a  

^a FRED HUTCHINSON CANCER RESEARCH CENTER   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIDE EFFECT;

ACUTE DISEASE; ADULT; BONE MARROW TRANSPLANTATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAFT VS HOST DISEASE; HUMAN; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR;

EID: 0025090676     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199009000-00033     Document Type: Article

References (26)

1. Lampert IA, Janossy G, Suitters AJ, et al. Immunological analysis of the skin in graft versus host disease. Clin Exp Immunol 1982; 50: 123.
2. Guillen FJ, Ferrara J, Hancock WW, et al. Acute cutaneous graft-versus-host disease to minor histocompatibility antigens in a murine model: evidence that large granular lymphocytes are effector cells in the immune response. Lab Invest 1986; 55: 35.
3. Piguet P-F, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med 1987; 166: 1280.
4. Cohen J. Cytokines as mediators of graft-versus-host disease. Bone Marrow Transplant 1988; 3: 193.
5. Mowat A Mel. Antibodies to IFN-y prevent immunologically me-diated intestinal damage in murine graft-versus-host reactions. Immunology 1989; 68: 18.
6. Volc-Platzer B, Majdic 0, Knapp W, et al. Evidence of HLA-DR antigen biosynthesis by human keratinocytes in disease. J Exp Med 1984; 159: 1784.
7. Nickoloff BJ, Basham TY, Merigan TC, Morhenn VB. Antiproliferative effects of recombinant alpha- and gamma-interferons on cultured human keratinocytes. Lab Invest 1984; 51: 697.
8. Reiss M, Sartorelli AC. Regulation of growth and differentiation of human keratinocytes by type beta transforming growth factor and epidermal growth factor. Cancer Res 1987; 47: 6705.
9. Symington F. Lymphotoxin, tumor necrosis factor, and gamma interferon are cytostatic for normal human keratinocytes. J Invest Dermatol 1989; 92: 798.
10. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantatin. N Engl J Med 1975; 292: 895.
11. Prince WS, Harder KJ, Saks S, Reed BR, Chen AB, Jones AJS. ELISA for quantitation of tumor necrosis factor-alpha in serum. J Pharm Biomed Analysis 1987; 5: 793.
12. Rosner B. Fundamentals of biostatistics. Boston: Duxbury Press, 1982.
13. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765.
14. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment. N Engl J Med 1983; 308: 302.
15. Matthews N. Tumour-necrosis factor from the rabbit: II. Production by monocytes. Br J Cancer 1979; 38: 310.
16. Cuturi MC, Murphy M, Costa-Giomi MP, Weinmann R, Perussia B, Trinchieri G. Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med 1987; 165: 1581.
17. Anegôn I, Cuturi MC, Trinchieri G, Perussia B. Interaction of Fc receptor (CD16) with ligands induces transcription of IL-2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med 1988; 167: 452.
18. Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor /3 and reversal by recombinant tumor necrosis factor a. J Exp Med 1987; 166: 991.
19. Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma- interferon, and interleukin-1. Nature 1986; 313: 86.
20. Beutler BA, Milsark IA, Cerami A. Cachetin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985; 135: 3972.
21. Beutler B, Milsark IW, Cerami A. Passive immunization against cachetin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869.
22. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachetin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662.
23. Grau GE, Fajardo LF, Piguet P-F, Allet B, Lambert P-H, Vassalli P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science.1987; 237: 1210.
24. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989; 170: 665.
25. Petersen CM, Moller BK. Immunological reactivity and bioactivity of tumour necrosis factor [Letter]. Lancet 1988; 1: 934.
26. Irlé C, Salamin AF, Bacigalupo A, et al. Serum TNF levels during graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1988; 3. (suppl): 127.